Abstract: A method for manufacturing a tank for storing flammable and combustible liquids underground includes fabricating a cylindrical tank core. Structurally, the core encloses a chamber and has an outer surface. Further, the core includes at least one opening for monitoring the integrity of the chamber positioned on the core's bottom centerline. Also, the tank includes a screen attached to the outer surface of the core along the bottom centerline to cover the opening. Moreover, a foil is affixed to the screen and to the outer surface of the tank core. Sprayed or applied on the foil is a seamless jacket formed from polyurea, thermoplastic, polyurethane or polyamine epoxy to encapsulate the tank core.

Abstract: A method for manufacturing a tank for storing flammable and combustible liquids underground includes fabricating a cylindrical tank core. Structurally, the core encloses a chamber and has an outer surface. Further, the core includes at least one opening for monitoring the integrity of the chamber positioned on the core's bottom centerline. Also, the tank includes a screen attached to the outer surface of the core along the bottom centerline to cover the opening. Moreover, a foil is affixed to the screen and to the outer surface of the tank core. Sprayed or applied on the foil is a seamless jacket formed from polyurea, thermoplastic, polyurethane or polyamine epoxy to encapsulate the tank core.

Abstract: A method for the treatment of a cutaneous, ocular, or mucosal pathological condition which is associated with immune response in a human or other mammal, that includes topical application of an effective amount of spiperone or a spiperone derivative or its pharmaceutically acceptable salt, in a pharmaceutically-acceptable diluent or carrier for topical application.

Abstract: A method for treating inflammatory bowel disease in a mammal that includes administering to the mammal and effective amount of spiperone or a spiperone derivative or a pharamaceutically acceptable salt thereof.

Abstract: A method for the treatment of a cutaneous, ocular, or mucosal pathological condition which is associated with immune response in a human or other mammal, that includes topical application of an effective amount of spiperone or a spiperone derivative or its pharmaceutically acceptable salt, in a pharmaceutically-acceptable diluent or carrier for topical application.

Abstract: A method for treating atopic dermatitis, hayfever, asthma and pruritis that includes topical or systemic application of an effective amount of buspirone or a buspirone derivative or its pharmaceutically acceptable salt, other than a quaternary salt, optionally in a pharmaceutically-acceptable diluent or carrier.

Abstract: A method for the topical or systemic treatment of disorders mediated by proteases which result in skin or mucosal lesions, and in particular, pemphigus, cicatricial pemphigoid, bullous pemphigoid, lichen planus, and canker sores, is disclosed wherein the host is treated with an effective amount of N-acetyl ysteine or a derivative thereof, or its pharmaceutically acceptable salt, optionally in a pharmaceutically acceptable diluent or carrier for systemic or topical delivery.

Abstract: A method for the treatment of a cutaneous, ocular, or mucosal pathological condition which is associated with an immune response in a human or other mammal, that includes topical application of an effective amount of buspirone or a buspirone derivative or its pharmaceutically acceptable salt, optionally in a pharmaceutically-acceptable diluent or carrier for topical application.

Abstract: A method for suppressing an immune response in a mammal by treating the mammal with an effective amount of spiperone derivative that is without significant neuroleptic effect due to decreased binding to serotonin and/or dopamine receptors as compared with unmodified or uncomplexed spiperone, or due to topical application which maximizes local immunosuppression while limiting systemic absorption and neuroleptic effects. The spiperone derivatives are capable of inhibiting classic contact hypersensitivity reactions.

Abstract: A method for suppressing an immune response in a mammal by systemically treating the mammal with an effective amount of buspirone that is capable of inhibiting classic contact hypersensitivity reactions.

Abstract: A method for suppressing an immune response in a mammal by treating the mammal with an effective amount of spiperone derivative that is without significant neuroleptic effect due to decreased binding to serotonin and/or dopamine receptors as compared with unmodified or uncomplexed spiperone, or due to topical application which maximizes local immunosuppression while limiting systemic absorption and neuroleptic effects. The spiperone derivatives are capable of inhibiting classic contact hypersensitivity reactions.

Abstract: The subject invention concerns a novel treatment for cancer. Specifically, the invention concerns the systemic administration of recombinant Platelet Factor Four (rPF4) to inhibit tumor growth in a mammal having metastatic cancer.

Abstract: A method for the treatment of a cutaneous, ocular, or mucosal pathological condition which is associated with immune response in a human or other mammal, that includes topical application of an effective amount of spiperone or a spiperone derivative or its pharmaceutically acceptable salt, in a pharmaceutically-acceptable diluent or carrier for topical application.

Abstract: The subject invention pertains to the use of recombinant PF4 (rPF4) as well as full length novel analogs (mutants) of rPF4, and peptide fragments thereof, to inhibit angiogenesis. rPF4, analogs, and certain fragments are shown to have utility for treating angiogenic diseases and for the inhibition of endothelial cell proliferation.